BioGend Therapeutics Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-102.59	-116.47	-156.33	-184.46	-138.49	-145.59
Depreciation & Amortization	48.33	51.19	55.02	53.18	28.19	19.19
Loss (Gain) From Sale of Assets	-	-	-	-	-	0.48
Loss (Gain) From Sale of Investments	-	-	-	-	-26.7	-
Loss (Gain) on Equity Investments	2.35	2.46	-10.34	-	11.35	14.24
Stock-Based Compensation	5.99	3.64	-	-	-	-
Other Operating Activities	-9.25	-13.02	-13.1	-29.26	-5.81	-0.35
Change in Accounts Receivable	-18.79	-20.67	-15.42	-6.22	-4.72	0.03
Change in Inventory	-4.29	0.58	-11.65	4.13	1.38	-7.9
Change in Accounts Payable	-0.16	2.06	0.08	1.6	-0.88	0.3
Change in Unearned Revenue	-	-2.5	-	-	-	-
Change in Other Net Operating Assets	1.03	-16.17	13.02	2.23	-1.12	2.48
Operating Cash Flow	-66.82	-98.91	-138.72	-168.78	-136.8	-117.13
Capital Expenditures	-0.49	-0.65	-26.04	-18.18	-0.67	-0.2
Cash Acquisitions	-	-	-	-	26.41	-
Sale (Purchase) of Intangibles	-	-	0.32	-	-	-
Investment in Securities	200	-6.24	-64	223.2	-159.97	-112.99
Other Investing Activities	-30.91	-1.31	0.08	-3.32	-0.04	-0.32
Investing Cash Flow	168.6	-8.2	-89.64	201.7	-134.27	-113.51
Long-Term Debt Repaid	-	-3.64	-3.58	-4.81	-1.78	-
Net Debt Issued (Repaid)	-3.69	-3.64	-3.58	-4.81	-1.78	-
Issuance of Common Stock	-	-	400	-	289.63	260
Other Financing Activities	-	-	-	-	-	0.9
Financing Cash Flow	-3.69	-3.64	396.42	-4.81	287.85	260.9
Foreign Exchange Rate Adjustments	-0.76	-0.74	-1.19	-0.79	-0.49	-
Net Cash Flow	97.33	-111.49	166.87	27.32	16.28	30.27
Free Cash Flow	-67.31	-99.56	-164.76	-186.96	-137.47	-117.33
Free Cash Flow Margin	-31.69%	-59.38%	-149.91%	-594.54%	-1483.13%	-8422.90%
Free Cash Flow Per Share	-0.55	-0.81	-1.37	-1.81	-1.36	-1.34
Cash Interest Paid	0.16	0.22	0.26	0.09	0.02	0.01
Cash Income Tax Paid	0.33	0.5	0.2	-0.18	-	0.12
Levered Free Cash Flow	-33.94	-57.11	-95.39	-98.09	-83.82	-69.96
Unlevered Free Cash Flow	-33.84	-56.97	-95.23	-98.04	-83.81	-69.96
Change in Working Capital	-12.21	-26.7	-13.97	-8.25	-5.34	-5.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.